ReviewFrontiers in cell and developmental biology2026
Exosomes in corneal diseases: advances in diagnosis and therapy.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis and treatment of corneal diseases still face many challenges. As nanoscale vesicles (30-150 nm in diameter), exosomes facilitate intercellular communication by transporting bioactive molecules such as proteins and nucleic acids. Exhibiting low immunogenicity, minimal toxicity, and engineering versatility, they hold strong promise for both diagnostic and therapeutic applications in corneal diseases. This review provides a comprehensive overview of the current understanding and future directions of exosome research in corneal diseases. We systematically compare traditional and emerging methods for exosome isolation and purification. We then discuss their expanding roles: (1) as diagnostic biomarkers and (2) as therapeutic agents or drug delivery systems, with an emphasis on representative examples and engineering innovations. Finally, we critically assess persistent challenges and outline essential research priorities for clinical translation. Looking forward, we highlight the need for standardized isolation protocols, large-scale production of clinical-grade exosomes, and targeted engineering strategies (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.